Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Pharmaceutical Research

• Publication date

  2004-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1023/B:PHAM.0000041466.84653.8cPMID 15497697
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A

  2003cited by this paper
• Uptake of rosuvastatin by isolated rat hepatocytes: comparison with pravastatin

  2003cited by this paper
• Statin-associated myopathy.

  2003cited by this paper
• Differential metabolism of midazolam in mouse liver and intestine microsomes: a comparison of cytochrome P450 activity and expression.

  2003cited by this paper
• Clinical Pharmacokinetics of Atorvastatin

  2003cited by this paper
• Effects of fibrates on metabolism of statins in human hepatocytes.

  2002cited by this paper
• Simvastatin and lovastatin, but not pravastatin, interact with MDR1

  2002cited by this paper
• Pharmacokinetic interactions of statins.

  2001cited by this paper
• Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins)

  2001cited by this paper
• In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.

  2001cited by this paper
• HMG‐CoA reductase inhibitors and P‐glycoprotein modulation

  2001cited by this paper
• Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

  2001cited by this paper
• Statin‐associated myopathy

  2001cited by this paper
• Rational use of in vitro P-glycoprotein assays in drug discovery.

  2001cited by this paper
• HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein

  2001cited by this paper
• Atorvastatin Transport in the Caco-2 Cell Model: Contributions of P-Glycoprotein and the Proton-Monocarboxylic Acid Co-Transporter

  2000cited by this paper
• Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

  1999cited by this paper
• Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations

  1999cited by this paper
• Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.

  1999cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• The physiological function of drug-transporting P-glycoproteins.

  1997cited by this paper
• P-glycoprotein substrates and antagonists cluster into two distinct groups.

  1997cited by this paper
• Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study.

  1996cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper
• Structure and function of P-glycoprotein in normal liver and small intestine.

  1993cited by this paper
• Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues.

  1990cited by this paper
• Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein.

  1989cited by this paper
• Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

  1986influential reference

• Risk of Opioid Overdose Associated with Concomitant Use of Methadone and Statins

  2024cites this paper
• The appropriateness of the use of statins for the secondary and primary prevention of atherosclerotic cardiovascular disease: a cross-sectional study from Jordan.

  2023cites this paper
• Mechanisms and Clinical Significance of Pharmacokinetic Drug Interactions Mediated by FDA and EMA-approved Hepatitis C Direct-Acting Antiviral Agents

  2023cites this paper
• Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects

  2023cites this paper
• Genomewide Association Study of Simvastatin Pharmacokinetics

  2022cites this paper
• Trivariate Linear Regression and Machine Learning Prediction of Possible Roles of Efflux Transporters in Estimated Intestinal Permeability Values of 301 Disparate Chemicals.

  2022cites this paper
• Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore

  2022cites this paper
• Regulation of Blood-Brain Barrier Transporters by Transforming Growth Factor-β/Activin Receptor-Like Kinase 1 Signaling: Relevance to the Brain Disposition of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors (i.e., Statins)

  2022cites this paper
• P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients

  2021cites this paper
• Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor- b Signaling in Human Endothelial Cells s

  2021influential citation
• Transport Properties of Statins by OATP1A2 and Regulation by Transforming Growth Factor-  (TGF-  ) Signaling in Human

  2020influential citation
• Novel insights into the organic solute transporter alpha/beta, OSTα/β: From the bench to the bedside.

  2020cites this paper
• P-glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Cancer Patients.

  2020cites this paper
• Chronopharmacology of simvastatin on hyperlipidaemia in high‐fat diet‐fed obese mice

  2020cites this paper
• Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery

  2020cites this paper
• Transport Properties of Statins by Organic Anion Transporting Polypeptide 1A2 and Regulation by Transforming Growth Factor-β Signaling in Human Endothelial Cells

  2020cites this paper
• Intestinal absorption and hepatic elimination of drugs in high‐fat high‐cholesterol diet‐induced non‐alcoholic steatohepatitis rats: exemplified by simvastatin

  2020cites this paper
• Cholesterol-lowering drugs the simvastatin and atorvastatin change the protease activity of pepsin: An experimental and computational study.

  2020cites this paper
• A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats

  2020cites this paper
• Repurposing approach identifies phenylpentanol derivatives as potent azole chemosensitizing agents effective against azole-resistant Candida species

  2019cites this paper
• TCRM_A_214938 921..936

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo studies, case reports, and population studies

  2019cites this paper
• The clinical significance of statins-macrolides interaction: comprehensive review of in vivo

  2019cites this paper
• Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins

  2018cites this paper
• Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics

  2018cites this paper
• In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems

  2018cites this paper
• Orally disintegrating tablets: formulation development, novel engineering solutions and fixed dose combinations

  2017cites this paper
• The influences of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of simvastatin, in relation to CYP3A4 inhibition.

  2017cites this paper
• Cardiovascular Ion Channel Inhibitor Drug-Drug Interactions with P-glycoprotein

  2017cites this paper
• Clinical Implications of P-Glycoprotein Modulation in Drug–Drug Interactions

  2017cites this paper
• Fixed-dose combination orally disintegrating tablets to treat cardiovascular disease: formulation, in vitro characterization and physiologically based pharmacokinetic modeling to assess bioavailability

  2017cites this paper
• Renal Drug Transporters and Drug Interactions

  2017cites this paper
• Intracellular drug bioavailability: a new predictor of system dependent drug disposition

  2017cites this paper
• High-Dose Metformin May Increase the Concentration of Atorvastatin in the Liver by Inhibition of Multidrug Resistance-Associated Protein 2.

  2017cites this paper
• Methodology and application for understanding cellular drug exposure

  2016cites this paper
• Brain cholesterol and the role of statins in neuroprotection

  2016cites this paper
• Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association

  2016cites this paper
• Intracellular unbound drug concentrations : methodology and application for understanding cellular drug exposure

  2016cites this paper
• Quantitative Estimation of P-glycorptein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance

  2015influential citation
• Impact of CYP2D6, CYP3A5, CYP2C19, CYP2A6, SLCO1B1, ABCB1, and ABCG2 gene polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid

  2015cites this paper
• Methyl-substitution of an iminohydantoin spiropiperidine β-secretase (BACE-1) inhibitor has a profound effect on its potency.

  2015cites this paper
• Hypoxia/Reoxygenation Stress Modulates Atorvastatin Transport at the Blood-Brain Barrier: A Role for Organic Anion Transporting Polypeptide

  2014cites this paper
• In Vitro Assessment of Drug-Drug Interaction Potential of Boceprevir Associated with Drug Metabolizing Enzymes and Transporters

  2013influential citation
• Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers

  2013cites this paper
• Microsoft Word-826811-file00.docx

  2013cites this paper
• Atorvastatin Treatment Induces Uptake and Efflux Transporters in Human Liver

  2013cites this paper
• Drug transporters in drug discovery and development

  2013cites this paper
• An integrated in vitro model for simultaneous assessment of drug uptake, metabolism, and efflux.

  2013cites this paper
• Transporter Studies in Drug Development: Experience to Date and Follow‐Up on Decision Trees From the International Transporter Consortium

  2013cites this paper
• DMD051698 1610..1615

  2013cites this paper
• Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors

  2013cites this paper
• Ivermectin induces P-glycoprotein expression and function through mRNA stabilization in murine hepatocyte cell line.

  2012cites this paper
• Drug–drug interaction study to assess the effects of atorvastatin co‐administration on pharmacokinetics and anti‐thrombotic properties of cilostazol in male Wistar rats

  2012cites this paper
• Effects of atorvastatin metabolites on induction of drug‐metabolizing enzymes and membrane transporters through human pregnane X receptor

  2012cites this paper
• Rhabdomyolysis secondary to drug interaction between atorvastatin, omeprazole, and dexamethasone

  2012cites this paper
• Understanding the Critical Disposition Pathways of Statins to Assess Drug–Drug Interaction Risk During Drug Development: It's Not Just About OATP1B1

  2012cites this paper
• Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats

  2012cites this paper
• Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2‐/‐ Mice and Intraindividual Variability in Human Subjects

  2012cites this paper
• A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes

  2011cites this paper
• Rifampin's Acute Inhibitory and Chronic Inductive Drug Interactions: Experimental and Model‐Based Approaches to Drug–Drug Interaction Trial Design

  2011cites this paper
• Use of cyclodextrins as solubilizing agents for simvastatin: effect of hydroxypropyl-β-cyclodextrin on lactone/hydroxyacid aqueous equilibrium.

  2011cites this paper
• In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.

  2011cites this paper
• Are Circulating Metabolites Important in Drug–Drug Interactions?: Quantitative Analysis of Risk Prediction and Inhibitory Potency

  2011cites this paper
• ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.

  2011cites this paper
• The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

  2011cites this paper
• Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

  2011cites this paper
• Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

  2011cites this paper
• Use of Transporter Knockdown Caco-2 Cells to Investigate the In Vitro Efflux of Statin Drugs

  2011cites this paper
• Dynamische Modellierung und Simulation des Arzneimittelmetabolismus in humanen Leberzellen: Identifizierbarkeit, Robustheit und inter-individuelle Variabilität

  2011cites this paper
• Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

  2010cites this paper
• Discovery and expanded SAR of 4,4-disubstituted quinazolin-2-ones as potent T-type calcium channel antagonists.

  2010cites this paper
• vitro clearance and permeability data

  2010cites this paper
• Differential interactions between statins and P‐glycoprotein: Implications for exploiting statins as anticancer agents

  2010cites this paper
• Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.

  2010cites this paper
• Evaluation of drug transporter interactions in drug discovery and development.

  2010cites this paper
• Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.

  2010cites this paper
• [Pharmacogenomics and the path towards personalized medicine].

  2010cites this paper
• Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data

  2010cites this paper
• Effects of lovastatin on the pharmacokinetics of nicardipine in rats.

  2010cites this paper
• LA FARMACOGENOMICA Y EL CAMINO HACIA LA MEDICINA PERSONALIZADA

  2010cites this paper
• De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.

  2010cites this paper
• Safety testing of metabolites: Expectations and outcomes.

  2009cites this paper
• Common genetic variation in the ABCB1 gene is associated with the cholesterol-lowering effect of simvastatin in males.

  2009cites this paper
• Atorvastatin is a Promising Partner for Antimalarial Drugs in Treatment of 1

  2009cites this paper
• Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism.

  2009cites this paper
• Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.

  2009cites this paper
• Methodology for development of a physiological model incorporating CYP3A and P-glycoprotein for the prediction of intestinal drug absorption.

  2009cites this paper
• Atorvastatin Is a Promising Partner for Antimalarial Drugs in Treatment of Plasmodium falciparum Malaria

  2009cites this paper
• Chapter 27 – Transporter Methods

  2008cites this paper
• Induction of P-glycoprotein expression and function in human intestinal epithelial cells (T84).

  2008cites this paper
• Discovery and X-ray crystallographic analysis of a spiropiperidine iminohydantoin inhibitor of beta-secretase.

  2008cites this paper
• Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters

  2008cites this paper
• ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

  2008cites this paper
• Pharmacokinetics of the Oral Direct Renin Inhibitor Aliskiren in Combination With Digoxin, Atorvastatin, and Ketoconazole in Healthy Subjects: The Role of P‐Glycoprotein in the Disposition of Aliskiren

  2008influential citation
• Effect of cyclosporine A and tacrolimus on OATP1B1 mediated transport of atorvastatin in an in vitro whole cell model

  2008cites this paper
• Drug Absorption Studies

  2008cites this paper
• In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism

  2008cites this paper
• Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization

  2008cites this paper
• Proline bis-amides as potent dual orexin receptor antagonists.

  2008cites this paper
• Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on OATPs and OCT1

  2008cites this paper